BackInfinity Pharmaceuticals Overview

Infinity Pharmaceuticals Total Liabilities

Infinity Pharmaceuticals's total liabilities is $59M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$58.64M
6.87% YoYΔ $-4.33M vs prior year quarter

Peer average

Loading

Infinity Pharmaceuticals Total Liabilities History

Loading

Infinity Pharmaceuticals vs. peers: Total Liabilities Comparison

Loading

Infinity Pharmaceuticals Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Infinity Pharmaceuticals (INFI) FAQ

Infinity Pharmaceuticals (INFI) currently reports a total liabilities of $59M as of June 2023. That compares with $63M in the prior-year period — down 6.9% year over year. Use the charts on this page to explore Infinity Pharmaceuticals's total liabilities history and peer comparisons.

Infinity Pharmaceuticals's total liabilities decreased from $63M to $59M — a 6.9% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Infinity Pharmaceuticals reported $59M in total liabilities as of June 2023. That compares with $63M in the prior-year period — down 6.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $59M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Infinity Pharmaceuticals, and consider following INFI for alerts when major investors trade the stock.

Infinity Pharmaceuticals is classified in the Healthcare sector. On total liabilities, it currently shows $59M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INFI with unrelated industries.